Untitled Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section
13 or 15(d) of
the Securities
Exchange Act of 1934
Date of Report
(Date of earliest event reported): August 27, 2018
AZURRX
BIOPHARMA, INC.
|
|
|
|
|
Delaware
|
001-37853
|
46-4993860
|
|
(State or Other
Jurisdiction of
Incorporation or
Organization)
|
(Commission File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
|
|
|
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, New York
|
11226
|
|
(Address of
principal executive
offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (646) 699-7855
(Name, address,
including zip code, and telephone number, including area code, of
agent for service of process)
NOT
APPLICABLE
(Former Name or
Former Address, if Changes Since Last Report)
Check the
appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the
following provisions):
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2)
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. [
]
Item
5.07
Submission of Matters to a Vote of Security Holders.
On August 27, 2018,
AzurRx BioPharma, Inc. (the “Company”) held its 2018 annual
meeting of stockholders (the “Annual Meeting”). The matters
voted upon at the Annual Meeting and the results of the voting are
set forth below.
Proposal No. 1- Election of Directors
|
|
For
|
|
Against
|
|
Johan (Thijs)
Spoor
|
8,961,067
|
|
133,000
|
|
Maged Shenouda
|
8,757,267
|
|
336,800
|
|
Edward J.
Borkowski
|
6,323,454
|
|
2,770,613
|
|
Alastair Riddell,
PhD.
|
8,220,859
|
|
873,208
|
|
Charles J.
Casamento
|
8,968,567
|
|
125,500
|
|
Vern Lee Schramm,
PhD.
|
8,971,067
|
|
123,000
|
The
Company’s Directors are elected by a plurality of the votes
cast. Accordingly, each of the nominees named above was elected to
serve on the Company’s Board of Directors until the Company's
2019 annual meeting of stockholders, or until their successors are
duly elected and qualified.
Proposal No. 2- Ratification of the Appointment of Mazars USA LLP
as the Company’s Independent Auditors for the Fiscal Year
Ending December 31, 2018
|
|
For
|
|
Against
|
|
Abstain
|
|
Votes
|
12,181,072
|
|
283
|
|
121,503
|
The vote required to approve this proposal was the
affirmative vote of a majority of the votes cast at the Annual
Meeting. Accordingly, stockholders ratified the appointment
of Mazars USA LLP
as the Company’s registered
public accounting firm auditors for the fiscal year ending December
31, 2018.
For more
information about the foregoing proposals, please review the
Company’s definitive proxy statement, filed with the
Securities and Exchange Commission on July 23,
2018.
On August 28, 2018, the Company
issued a press release announcing that it plans to present at the
Rodman and Renshaw 20th Annual Global Investment Conference
in New York at the St. Regis Hotel on Wednesday,
September 5th at 5:30 p.m. EDT.
A copy of the press release is attached as
Exhibit 99.1 to this Current Report on Form 8-K, and
is incorporated herein by
reference.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
See
Exhibit Index.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August
29, 2018
|
|
By:
|
/s/ Johan M.
Spoor
|
|
|
Name: Johan M. Spoor
|
|
|
Title: Chief Executive Officer
|
Exhibit
Index
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
|
Press
Release, dated August 28, 2018
|